ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma

Marek Trněný

Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions

Share this video  
Similar topics